These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1843267)

  • 1. Effect of intermittent oral 1,25(OH)2D3 therapy on bone Gla protein in dialysis patients.
    Miki T; Nakatsuka K; Nishizawa Y; Emoto M; Morita A; Tabata T; Matsushita Y; Inoue T; Morii H
    Endocrinol Jpn; 1991 Oct; 38(5):479-83. PubMed ID: 1843267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
    Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
    Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory effect of calcium-regulating hormones on the synthesis and/or secretion of bone gamma-carboxyglutamic acid-containing protein in chick embryonic calvaria in vitro.
    Tsutsumi C; Hoshiba K; Moriuchi S; Orimo H; Hosoya N
    J Nutr Sci Vitaminol (Tokyo); 1986 Apr; 32(2):157-69. PubMed ID: 3020205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum bone Gla-protein increases following short-term oral administration of active vitamin D3 in the elderly with vitamin D deficiency].
    Nakatsuka K; Kosaka H; Kiichiro S; Takamoto S; Onishi T; Miki T; Nishizawa Y; Morii H
    Nihon Ronen Igakkai Zasshi; 1997 Sep; 34(9):733-8. PubMed ID: 9430985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dietary phosphorus restriction on secondary hyperparathyroidism in hemodialysis patients during intermittent oral high-dose 1,25(OH)2D3 treatment.
    Tabata T; Shoji S; Morita A; Emoto M; Inoue T; Miki T; Nishizawa Y; Morii H
    J Nutr Sci Vitaminol (Tokyo); 1991 Dec; 37 Suppl():S105-12. PubMed ID: 1820436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
    Shigematsu T; Kawaguchi Y; Unemura S; Yamamoto H; Momose M; Yokoyama K; Wakabayashi Y; Ikeda M; Hasegawa T; Sakai O
    Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
    Perez-Mijares R; Gomez-Fernandez P; Almaraz-Jimenez M; Ramos-Diaz M; Rivero-Bohorquez J
    Am J Nephrol; 1993; 13(2):149-54. PubMed ID: 8342582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up.
    Coen G; Mazzaferro S; Bonucci E; Taggi F; Ballanti P; Bianchi AR; Donato G; Massimetti C; Smacchi A; Cinotti GA
    Kidney Int; 1985 Nov; 28(5):783-90. PubMed ID: 3878905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.
    Ito H; Ogata H; Yamamoto M; Takahashi K; Shishido K; Takahashi J; Taguchi S; Kinugasa E
    Clin Nephrol; 2009 Jun; 71(6):660-8. PubMed ID: 19473635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
    Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
    Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].
    Matuszkiewicz-Rowińska J; Niemczyk S; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1993 Feb; 89(2):95-101. PubMed ID: 8502602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum and dialysate osteocalcin levels in hemodialysis and peritoneal dialysis patients and after renal transplantation.
    Epstein S; Traberg H; Raja R; Poser J
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1253-6. PubMed ID: 3889031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ; Yang CS; Ferng SH; Chen LY
    Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.